Insulin Pump Therapy in Type 1 Diabetes-Merging Technology with Diabetes Care

Thabit, Hood

doi:10.3844/amjsp.2012.93.99

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood glucose control is the most rigorous research area. Insulin-dependent diabetes is called Type 1 diabetes (Andras et al, 2009;Bergenstal et al, 2010;Thabit, 2012;Anantha et al, 2013), is the most frequently occurred diabetes to adults. The other diabetes is called Type 2 diabetes which is insulin-independent diabetes (Ismail et al, 2013), our research is concentrated on Type 1 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Automatic Glucose Insulin Regulation System-Comparison of Embedded Control Design and Harr Wavelet Method for Type-1 Diabetes

Arangasamy¹,

Sundararajan²,

Vennila³

et al. 2014

American Journal of Applied Sciences

View full text Add to dashboard Cite

This article is aimed to inject insulin for type 1 diabetes using pumping the insulin with respect to meal disturbance. We have used the embedded linear parameter varying methodology controller and the final results were compared with the Harr wavelet mathematical values. In this article, there are three things we need to focus. First is the sensor values which is to be monitored from the sensors and next is the lab information. Depending on the patients test details the insulin has to be injected. The comparison of lab details with the Patients current sensor values play a vital role in determining the insulin level for a patient. Finally the feedback has to be obtained with the help of those comparisons and it has to be sent once again as a loop to the controller for later comparison and also for database information. The embedded controller is the key element for updating all the information about the patient and it will control all the parameters of the board. The experimental results shows that the proposed method has much better potential in terms of solution accuracy as 97% and better convergence speed in comparison with Haar Wavelet Model which proved 89.09% of accuracy of the assured values of our experiments.

show abstract

Section: Introductionmentioning

confidence: 99%

Automatic Glucose Insulin Regulation System-Comparison of Embedded Control Design and Harr Wavelet Method for Type-1 Diabetes

Arangasamy¹,

Sundararajan²,

Vennila³

et al. 2014

American Journal of Applied Sciences

View full text Add to dashboard Cite

show abstract

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics

Pozzilli

Battelino

Danne

et al. 2015

Diabetes Metabolism Res

130

View full text Add to dashboard Cite

SummaryThe level of glycaemic control necessary to achieve optimal short‐term and long‐term outcomes in subjects with type 1 diabetes mellitus (T1DM) typically requires intensified insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion. For continuous subcutaneous insulin infusion, the insulins of choice are the rapid‐acting insulin analogues, insulin aspart, insulin lispro and insulin glulisine. The advantages of continuous subcutaneous insulin infusion over multiple daily injections in adult and paediatric populations with T1DM include superior glycaemic control, lower insulin requirements and better health‐related quality of life/patient satisfaction. An association between continuous subcutaneous insulin infusion and reduced hypoglycaemic risk is more consistent in children/adolescents than in adults. The use of continuous subcutaneous insulin infusion is widely recommended in both adult and paediatric T1DM populations but is limited in pregnant patients and those with type 2 diabetes mellitus. All available rapid‐acting insulin analogues are approved for use in adult, paediatric and pregnant populations. However, minimum patient age varies (insulin lispro: no minimum; insulin aspart: ≥2 years; insulin glulisine: ≥6 years) and experience in pregnancy ranges from extensive (insulin aspart, insulin lispro) to limited (insulin glulisine). Although more expensive than multiple daily injections, continuous subcutaneous insulin infusion is cost‐effective in selected patient groups. This comprehensive review focuses on the European situation and summarises evidence for the efficacy and safety of continuous subcutaneous insulin infusion, particularly when used with rapid‐acting insulin analogues, in adult, paediatric and pregnant populations. The review also discusses relevant European guidelines; reviews issues that surround use of this technology; summarises the effects of continuous subcutaneous insulin infusion on patients' health‐related quality of life; reviews relevant pharmacoeconomic data; and discusses recent advances in pump technology, including the development of closed‐loop ‘artificial pancreas’ systems. © 2015 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.

show abstract

Comprehensive approach to the management of diabetes: offering improved outcomes for diabetics and the healthcare system

Perfetti¹

2013

Diabetes Management

View full text Add to dashboard Cite

Insulin Pump Therapy in Type 1 Diabetes-Merging Technology with Diabetes Care

Cited by 4 publications

References 25 publications

Automatic Glucose Insulin Regulation System-Comparison of Embedded Control Design and Harr Wavelet Method for Type-1 Diabetes

Automatic Glucose Insulin Regulation System-Comparison of Embedded Control Design and Harr Wavelet Method for Type-1 Diabetes

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics

Comprehensive approach to the management of diabetes: offering improved outcomes for diabetics and the healthcare system

Contact Info

Product

Resources

About